ELVN
NASDAQ
US
Enliven Therapeutics, Inc. - Common Stock
$38,83
▲ +$1,04
(+2,75%)
Vol 811K
2
Skor Kualitas
fail
Pendapatan ✗
Laba Bersih ✗
>IPO ✗
Kap. Pasar
$913.9M
ROE
-24,9%
D/E
0,00
Beta
0,27
52W
$13–$25
Konsensus Wall Street
16 analis · Apr 20265
Beli Kuat
10
Beli
1
Tahan
0
Jual
0
Jual Kuat
93,8%
Peringkat Beli
Grafik Harga
Saham Serupa
Pendapatan
Tingkat beat: 50,0%
Laporan Berikutnya
Mei 12, 2026
Estimasi EPS: $-0,47
| Kuartal | EPS Estimasi | EPS Aktual | Kejutan |
|---|---|---|---|
| Mar 2026 | $-0,47 | — | — |
| Des 2025 | $-0,39 | $-0,48 | $-0,09 |
| Sep 2025 | $-0,44 | $-0,32 | +$0,12 |
| Jun 2025 | $-0,54 | $-0,49 | +$0,05 |
Pendapatan & Laba Kuartalan
| Kuartal | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Pendapatan | — | — | — | — | — | — |
| Laba Bersih | — | -$23.2M | -$28.5M | -$25.3M | -$20.1M | -$29.7M |
Tren Fundamental
| Metrik | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -29.1% | -31.8% | -29.1% | -29.1% | -29.1% | -24.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 32.58 | 21.06 | 32.58 | 32.58 | 32.58 | 32.95 |
Rasio Utama
ROA (TTM)
-24,0%
P/B
3,5
EPS (TTM)
$-1,85
CF/Share
$-0,72
52W High
$25,37
52W Low
$13,30
$13,30
Rentang 52 Minggu
$25,37
Kesehatan Keuangan
Arus Kas Bebas
-$15.8M
Utang Bersih
-$98.5M
Kas
$98.9M
Total Utang
$399K
Per tanggal Des 31, 2025
Як ELVN виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Micro-cap Pharmaceuticals (All) · 171 компаній
Оцінка ELVN vs аналоги Pharmaceuticals
P/E
—
▼
0%
di bawah
rekan
(22,4)
vs Rekan
vs Industri
Undervalued
P/S
—
▼
0%
di bawah
rekan
(5,0)
vs Rekan
vs Industri
Overvalued
P/B
3,6
▲
67%
di atas
rekan
(2,1)
vs Rekan
vs Industri
Lebih mahal
Дивідендна дохідність
—
▼
0%
di bawah
rekan
(2,0%)
vs Rekan
vs Industri
Yield rendah
Прибутковість ELVN vs аналоги Pharmaceuticals
ROE
-24,9%
▲
54%
di atas
rekan
(-54,3%)
vs Rekan
vs Industri
Di bawah rata-rata
Net margin
—
▼
0%
di bawah
rekan
(-47,4%)
vs Rekan
vs Industri
Tingkat atas
Валова маржа
—
▼
0%
di bawah
rekan
(68,3%)
vs Rekan
vs Industri
Sejajar
ROA
-24,0%
▲
36%
di atas
rekan
(-37,4%)
vs Rekan
vs Industri
Di bawah rata-rata
Фінансове здоровʼя ELVN vs аналоги Pharmaceuticals
D/E ratio
0,0
▼
100%
di bawah
rekan
(1,5)
vs Rekan
vs Industri
Utang rendah
Поточна ліквідність
33,0
▲
881%
di atas
rekan
(3,4)
vs Rekan
vs Industri
Likuiditas kuat
Beta
0,3
▼
71%
di bawah
rekan
(0,9)
vs Rekan
vs Industri
Lebih volatil
Радар фундаменталів ELVN
ELVN
Median rekan
Industri
ELVN прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ELVN vs аналоги: ключові метрики
Aktivitas Orang Dalam
NeutralPembelian
0
Penjualan
0
COLLINS HELEN LOUISE
Officer · Mar 25
40000 shs
COLLINS HELEN LOUISE
Officer · Mar 25
40000 shs
COLLINS HELEN LOUISE
Officer · Mar 17
5000 shs
COLLINS HELEN LOUISE
Officer · Mar 17
5000 shs
COLLINS HELEN LOUISE
Officer · Mar 10
40000 shs
COLLINS HELEN LOUISE
Officer · Mar 10
40000 shs
HOHL BENJAMIN
Chief Financial Officer · Mar 06
10000 shs
COLLINS HELEN LOUISE
Officer · Feb 17
45000 shs
HEYMAN RICHARD A
Director · Feb 17
1230 shs
COLLINS HELEN LOUISE
Officer · Feb 17
45000 shs
Terakhir 90 hari
Pemegang Terbesar
Top 5: 45,66%Orbimed Advisors LLC.
13,31%
$309.1M
FMR, LLC
11,89%
$276.0M
Commodore Capital Lp
7,85%
$182.2M
Vestal Point Capital, LP
6,40%
$148.7M
Fairmount Funds Management …
6,21%
$144.1M
Per tanggal Des 31, 2025
Berita Terbaru
Belum ada berita terkait